Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Similar articles for PubMed (Select 20156221)

1.

Cost-effectiveness of screening for recurrent hepatocellular carcinoma after liver transplantation.

Ladabaum U, Cheng SL, Yao FY, Roberts JP.

Clin Transplant. 2011 Mar-Apr;25(2):283-91. doi: 10.1111/j.1399-0012.2010.01212.x.

PMID:
20156221
2.

Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis.

Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB.

Am J Gastroenterol. 2003 Mar;98(3):679-90.

PMID:
12650806
3.
5.

Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis.

Patel D, Terrault NA, Yao FY, Bass NM, Ladabaum U.

Clin Gastroenterol Hepatol. 2005 Jan;3(1):75-84.

PMID:
15645408
6.
7.

Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence.

Parfitt JR, Marotta P, Alghamdi M, Wall W, Khakhar A, Suskin NG, Quan D, McAllister V, Ghent C, Levstik M, McLean C, Chakrabarti S, Garcia B, Driman DK.

Liver Transpl. 2007 Apr;13(4):543-51.

8.

Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.

Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F, Gramantieri L, Zanetti M, Sherman M.

Gut. 2001 Feb;48(2):251-9.

9.

Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness.

Yuen MF, Lai CL.

Ann Oncol. 2003 Oct;14(10):1463-7. Review.

10.

Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C.

Lin OS, Keeffe EB, Sanders GD, Owens DK.

Aliment Pharmacol Ther. 2004 Jun 1;19(11):1159-72.

11.

Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma.

Lee KK, Kim DG, Moon IS, Lee MD, Park JH.

J Surg Oncol. 2010 Jan 1;101(1):47-53. doi: 10.1002/jso.21415.

PMID:
19798686
12.

Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model.

Saab S, Ly D, Nieto J, Kanwal F, Lu D, Raman S, Amado R, Nuesse B, Durazo F, Han S, Farmer DG, Ghobrial RM, Yersiz H, Chen P, Schwegel K, Goldstein LI, Tong M, Busuttil RW.

Liver Transpl. 2003 Jul;9(7):672-81.

13.

Liver transplantation in patients with hepatocellular carcinoma across Milan criteria.

Herrero JI, Sangro B, Pardo F, Quiroga J, Iñarrairaegui M, Rotellar F, Montiel C, Alegre F, Prieto J.

Liver Transpl. 2008 Mar;14(3):272-8. doi: 10.1002/lt.21368.

14.

Efficacy and cost of a hepatocellular carcinoma screening program at an Australian teaching hospital.

Qian MY, Yuwei J R, Angus P, Schelleman T, Johnson L, Gow P.

J Gastroenterol Hepatol. 2010 May;25(5):951-6. doi: 10.1111/j.1440-1746.2009.06203.x.

PMID:
20546449
15.

Screening for hepatocellular carcinoma: why, when, how?

Arguedas MR.

Curr Gastroenterol Rep. 2003 Feb;5(1):57-62. Review.

PMID:
12530949
16.
17.

Liver transplantation and recurrent hepatocellular carcinoma: predictive value of nodule size in a retrospective and explant study.

Grasso A, Stigliano R, Morisco F, Martines H, Quaglia A, Dhillon AP, Patch D, Davidson BR, Rolles K, Burroughs AK.

Transplantation. 2006 Jun 15;81(11):1532-41.

PMID:
16770242
18.
19.

Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation.

Llovet JM, Mas X, Aponte JJ, Fuster J, Navasa M, Christensen E, Rodés J, Bruix J.

Gut. 2002 Jan;50(1):123-8.

20.

Feasibility of salvage liver transplantation for patients with recurrent hepatocellular carcinoma.

Hu RH, Ho MC, Wu YM, Yu SC, Lee PH.

Clin Transplant. 2005 Apr;19(2):175-80.

PMID:
15740552
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk